首页> 中文期刊> 《世界核心医学期刊文摘:胃肠病学分册》 >瑞典非选择性慢性丙型肝炎患者在干扰素和利巴韦林联用前后的健康相关生活质量

瑞典非选择性慢性丙型肝炎患者在干扰素和利巴韦林联用前后的健康相关生活质量

         

摘要

Objective. To study the relationship between health-related quality of life (HRQOL) and mode of acquisition, treatment discontinuations, drop in haemoglobin levels and treatment outcome in patients with chronic hepatitis C (CHC). Material and methods. Consecutive unselected Swedish patients with CHC completed the SF-36 questionnaire before, during and after treatment with interferon and ribavirin. Results. At baseline, HRQOL was reduced in all SF-36 subscales in our patients (n = 147) as compared with the general Swedish population. Former intravenous drug users (IVDUs) scored significantly lower in social function (p = 0.03) and mental health (p = 0.03) than patients who had acquired their infection from blood transfusions (PTH). A decline of > 40 points in HRQOL from baseline to week 12 was noticed in the role limitations-physical (RP) score for the IVDU and PTHgroups (p < 0.0001 and 0.001, respectively). Patients with a ≥20%fall in haemoglobin levels at treatment week 12 had a significantly poorer RP (p = 0.006) and role limitations-emotional score (p < 0.02) than patients with a < 10%fall. Early treatment dropouts had significantly lower HRQOL scores at baseline than adherent patients. At follow-up, sustained viral responders had significantly higher scores than non-responders. Conclusions. Swedish outpatients with CHC have a marked reduction in their HRQOL as compared to the general population. Therapy reduces HRQOL most substantially in those with a marked reduction in haemoglobin. Early dropouts from therapy have significantly lower HRQOL scores at baseline than adherent patients, and sustained viral responders improve their HRQOL significantly more than nonresponders.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号